- Home
- RVPHW vs BEATW Comparison
RVPHW vs BEATW Comparison
Compare RVPHW & BEATW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- BEATW
- Stock Information
- Founded
- RVPHW N/A
- BEATW N/A
- Country
- RVPHW United States
- BEATW United States
- Employees
- RVPHW 15
- BEATW N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- BEATW Retail: Computer Software & Peripheral Equipment
- Sector
- RVPHW Health Care
- BEATW Technology
- Exchange
- RVPHW Nasdaq
- BEATW Nasdaq
- Market Cap
- RVPHW N/A
- BEATW N/A
- IPO Year
- RVPHW 2018
- BEATW 2021
- Fundamental
- Price
- RVPHW $0.14
- BEATW $0.61
- Analyst Decision
- RVPHW
- BEATW
- Analyst Count
- RVPHW 0
- BEATW 0
- Target Price
- RVPHW N/A
- BEATW N/A
- AVG Volume (30 Days)
- RVPHW N/A
- BEATW N/A
- Earning Date
- RVPHW N/A
- BEATW N/A
- Dividend Yield
- RVPHW N/A
- BEATW N/A
- EPS Growth
- RVPHW N/A
- BEATW N/A
- EPS
- RVPHW N/A
- BEATW N/A
- Revenue
- RVPHW N/A
- BEATW N/A
- Revenue This Year
- RVPHW N/A
- BEATW N/A
- Revenue Next Year
- RVPHW N/A
- BEATW N/A
- P/E Ratio
- RVPHW N/A
- BEATW N/A
- Revenue Growth
- RVPHW N/A
- BEATW N/A
- 52 Week Low
- RVPHW N/A
- BEATW N/A
- 52 Week High
- RVPHW N/A
- BEATW N/A
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- BEATW N/A
- Support Level
- RVPHW N/A
- BEATW N/A
- Resistance Level
- RVPHW N/A
- BEATW N/A
- Average True Range (ATR)
- RVPHW 0.00
- BEATW 0.00
- MACD
- RVPHW 0.00
- BEATW 0.00
- Stochastic Oscillator
- RVPHW 0.00
- BEATW 0.00
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.